Deucrictibant Achieves All Primary and Secondary Endpoints in Late-Stage Trial for Rapid HAE Treatment

Pharvaris (PHVS) stock surged approximately 7% on the heels of impressive Phase 3 results from its RAPIDe-3 trial, which evaluated the company’s lead candidate Deucrictibant for acute attacks in hereditary angioedema patients. The pivotal trial, which recruited 134 participants across 24 countries, represents the most globally diverse population to date in on-demand HAE treatment research.

Trial Success: Fast-Acting Relief Demonstrates Clinical Advantage

The RAPIDe-3 study centered on Deucrictibant 20 mg immediate-release capsules administered for acute symptom management in patients aged 12 and above. The drug successfully achieved its primary objective, delivering median symptom relief within 1.28 hours—a dramatic improvement over placebo’s 12+ hour response time. Beyond the primary measure, all 11 secondary endpoints were also hit, underscoring the compound’s robust efficacy profile.

Most notably, median time to End of Progression reached 17.47 minutes with Deucrictibant versus 228.67 minutes for placebo. Complete symptom resolution occurred in 11.95 hours compared to more than 24 hours in the control group. These findings suggest a compelling treatment advantage for patients experiencing acute HAE attacks.

Clinical and Safety Profile: Single Dose, Minimal Intervention

Real-world efficacy indicators prove equally compelling. Among enrolled patients, 83% of HAE attacks were managed with a single capsule dose, while 93% required no additional rescue medications. The safety data showed no treatment-related serious adverse events and zero discontinuations due to tolerability concerns—a clean safety profile critical for an on-demand therapy.

Deucrictibant operates by blocking bradykinin signaling through the B2 receptor, a mechanism designed to interrupt the inflammatory cascade underlying angioedema attacks. Dr. Marc A. Riedl, the study’s principal investigator, emphasized that the combination of rapid onset and sustained symptom control positions the oral therapy as a practical advancement for HAE management.

Future Development Path and Market Potential

Pharvaris intends to file a New Drug Application with the U.S. FDA during the first half of 2026, seeking approval for on-demand HAE treatment. Simultaneously, the company continues long-term safety monitoring through the ongoing RAPIDe-2 Part B open-label extension study. Looking further ahead, the Phase 3 CHAPTER 3 trial is investigating Deucrictibant’s potential in prophylactic settings, with data anticipated in late 2026.

A successful prophylactic indication could position Deucrictibant as the first oral agent offering both acute and preventive control of bradykinin-mediated angioedema, potentially reshaping HAE in treatment paradigms.

Market Response

PHVS closed the previous trading session at $24.12, down 1.88%. Following today’s positive topline release, premarket activity pushed the stock up nearly 7% to approximately $25, reflecting investor optimism about the clinical milestone and regulatory pathway ahead.